Navigation Links
Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
Date:7/7/2013

LAUSANNE, Switzerland, July 4, 2013 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.

Under the research framework, Quartz Bio will apply its leading expertise in bioinformatics to support Debiopharm translational projects in terms of computational analyses and biomarker discovery. Projects are expected to range from preclinical Next-Generation Sequencing to clinical biomarker data analyses.

"We are delighted to collaborate with Debiopharm," said Dr. Jerome Wojcik, CEO of Quartz Bio. "Debiopharm's pioneering biomarker projects are a unique opportunity for Quartz Bio to contribute to the implementation of Precision Medicine, thus demonstrating that bioinformatics science can bring substantial benefits to patients."

"We look forward to collaborating with Quartz Bio," commented Dr. Hiroaki Tanaka, Director of Personalized Medicine at Debiopharm. "Their longstanding clinical bioinformatics experience made them an ideal partner to support our biomarker projects in our clinical trials and extract from data the relevant information required for personalized therapy development."

About Quartz Bio

Quartz Bio SA is a clinical bioinformatics service company specialized in exploratory biomarker data analyses for the generation of precision medicine hypotheses. Quartz Bio provides modular data analysis solutions to the major steps of the biomarker development process. These include: biomarker study design, biomarker data quality control, statistical analysis and scientific reporting. The capital of the company is entirely owned by its employees, who are scientists from diverse educational backgrounds with a common track record of 6 to 10 years clinical bioinformatics experience in the pharmaceutical sector.

For more information, please visit the company's web site: http://www.quartzbio.com

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses and develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and access to the largest number of patients worldwide. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics to profit from the unique advantages of personalized medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information about Debiopharm Group™: http://www.debiopharm.com

Debiopharm International SA Contact
Beatrice Hirt
Communication Coordinator
beatrice.hirt@debiopharm.com
Tel.: +41-21-321-01-11

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel.: +44-(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel.: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE The Debiopharm Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
2. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
3. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
4. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
5. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
6. Ventana Supports World Patient Safety Day, July 25
7. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
8. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
9. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
10. Henry Schein Cares Supports Alliance for Oral Health Across Borders Leadership Event
11. Cardinal Health Supports Future Pharmacists With Nearly $1 Million In Scholarships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017 ML Capital ... to publish an online presentation tomorrow, January 19 ... forecast for 2017. Management reports that the forecast ... sales performance from its existing operations, and the ... into the Cannabis sector through a partnership ...
(Date:1/18/2017)... 2017  Astellas Pharma Inc. (President and CEO: ... its participation in Access Accelerated, a global, multi-stakeholder ... prevention, diagnostics and treatment in low-income and lower-middle ... companies and in collaboration with the World Bank ... (UICC), Astellas will work towards the United Nations ...
(Date:1/17/2017)... 17, 2017 North America Insulin Delivery Market ... "North America Insulin Delivery Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segments - Insulin Pens, Insulin Pumps, Insulin Syringes ... provides company shares and distribution shares data for each ...
Breaking Medicine Technology:
(Date:1/18/2017)... Charlottesville, Virginia (PRWEB) , ... January 18, 2017 , ... ... New studies are released almost daily linking gut health to chronic disease, mental health ... the New Year ” as an important resolution to consider. , For one Charlottesville ...
(Date:1/18/2017)... SHANGHAI, China – , ... ... public health organization NSF International has certified the first drinking ... 53: Drinking Water Treatment Units – Health Effects, an American ... that MicroCeramics’ NanoNose Pitcher Filter System filters the water to ...
(Date:1/18/2017)... ... January 18, 2017 , ... A Palm Beach doctor ... Smile Train, an international charity that provides free surgery to poor children suffering from ... in the past I have run to support the efforts of the American Heart ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... offering asset protection and financial planning services to families and business owners in ... event aimed at supporting children with developmental disabilities. , The Lakemary Center is ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that Mr. Michael Merges, Director of Strategic Growth, ... be held at the Mayflower Hotel, Washington DC, on Jan. 24 – 26, ...
Breaking Medicine News(10 mins):